ProCE Banner Activity

Emerging NASH Treatments

Podcast Episodes
Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis.

Released: July 01, 2020

Expiration: June 30, 2021

No longer available for credit.

Share

Faculty

Philip N. Newsome

Philip N. Newsome, PhD, FRCPE

Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom

Provided by

Provided by the American Gastroenterology Association.
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Gilead

Intercept Pharmaceuticals

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Philip N. Newsome, PhD, FRCPE

Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom

Philip N. Newsome, PhD, FRCPE, has disclosed that he has received, on behalf of the University of Birmingham, consulting fees from Afimmune, Boehringer Ingelheim, Gilead Sciences, Intercept, Novo Nordisk, Pfizer, and Shire and funds for research support from Boehringer Ingelheim and Novo Nordisk.

Staff Disclosure

Staff

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.